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Abstract
Heterozygous disruptions in FOXP1 are responsible for developmental delay, intellectual disability and speech deﬁcit.
Heterozygous germline PTCH1 disease-causing variants cause Gorlin syndrome. We describe a girl with extreme
megalencephaly, developmental delay and severe intellectual disability. Dysmorphic features included prominent forehead,
frontal hair upsweep, ﬂat, wide nasal bridge, low-set, abnormally modelled ears and post-axial cutaneous appendages on the
hands. Brain MRI showed partial agenesis of the corpus callosum and widely separated leaves of the septum pellucidum.
Exome sequencing of a gene set representing a total of 4813 genes with known relationships to human diseases revealed an
already known heterozygous de novo nonsense disease-causing variant in FOXP1 (c.1573C>T, p.Arg525Ter) and a
heterozygous novel de novo frameshift nonsense variant in PTCH1 (c.2834delGinsAGATGTTGTGGACCC, p.
Arg945GlnfsTer22). The composite phenotype of the patient seems to be the result of two monogenic diseases, although
more severe than described in conditions due to disease-causing variants in either gene.
Introduction
FOXP1 (forkhead box protein P1; Online Mendelian
Inheritance in Man (OMIM) 605515) is one of the four
members of the FOXP subfamily (FOXP1–4) and acts as a
transcriptional repressor [1]. The FOXP1 gene is located on
chromosome 3p13. Monogenic FOXP1 pathogenic variants
and more extensive 3p chromosomal deletions encompass-
ing FOXP1 have been reported previously [2–4]. Even-
tually, a FOXP1 mutation-related phenotype (OMIM
613670) as a recognizable entity has been outlined with
intellectual disability, speciﬁc language impairment with or
without autistic spectrum disorder and dysmorphic features
[3–5].
The PTCH1 (patched homologue 1, OMIM 601309)
gene on chromosome 9q22.3 encodes a transmembrane
glycoprotein [6] which functions as a hedgehog (HH)
receptor and regulates HH signalling at the primary cilium
[6, 7]. Heterozygous germline PTCH1 pathogenic variants
cause Gorlin syndrome (OMIM 109400), an autosomal
dominant disorder that predisposes affected individuals to
developmental defects and tumourigenesis [6–8].
Megalencephaly is deﬁned as an oversized brain with
head circumference exceeding the age-related mean by two
or more standard deviations [9]. A tendency to mega-
lencephaly has been reported in both FOXP1- and PTCH1-
related conditions [3–5, 7–9]. We describe here a girl with
co-occurrence of heterozygous disease-causing variants in
both FOXP1 and PTCH1 genes in association with extreme
megalencephaly, unreported in mutations of either gene,
dysmorphic features, abnormal corpus callosum, and pro-
found intellectual disability.
Case report
The proband, a girl, was born from the second pregnancy at
36 weeks of gestation via vaginal delivery with a birth weight
of 2870 g (+0.4 SD), length of 50 cm (+0.8 SD) and head
circumference of 37 cm (+1.8 SD). Dysmorphic features,
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such as prominent forehead, frontal hair upsweep, arched
eyebrows, strabismus, broad nasal bridge, short nose with
broad tip, long philtrum, pointed chin, low-set, abnormally
modelled ears and symmetrical post-axial cutaneous appen-
dages (skin tags) on both hands were observed (Fig. 1a, b, d).
Progressive growth of her head circumference was noted
(Fig. 1c); it was 58 cm (+6.1 SD) at the age of 4 years, and
61 cm (+7.1 SD) at the age of 8 years. Her height was 129 cm
(+0.2 SD) and weight 33 kg (+1.3 SD) at 8 years of age. Her
motor and cognitive development was severely delayed.
Brunet-Lézine test at the age of 2.5 years showed a devel-
opmental quotient of 40. On examination, generalized hypo-
tonia and preserved deep tendon reﬂexes were observed.
Brain magnetic resonance imaging (MRI) revealed partial
agenesis of the corpus callosum (Fig. 1e) and widely sepa-
rated leaves of the septum pellucidum (Fig. 1f). Brain com-
puted tomography was not performed. Abdominal and cardiac
ultrasound, chest X-ray and dental radiography were normal.
Methods
Routine chromosomal analysis was performed by standard
techniques. Genomic DNA was extracted from peripheral
blood samples with the Puregene kit (Gentra) after
obtaining informed consent. Copy number changes were
investigated by Affymetrix 750K array. The Illumina
Trusight One Exome Sequencing Panel (Illumina Inc., San
Diego, CA, USA), covering the coding region of 4813
clinically relevant genes, was applied using Illumina MiSeq
(Illumina Inc., San Diego, CA, USA). Variants were ﬁl-
tered based on severity and frequency against public var-
iant databases including single-nucleotide polymorphism
database (dbSNP), ClinVar, Exome Aggregation Con-
sortium (ExAC), Exome Variant Server (EVS) and in-
house clinical exome database of 140 unrelated Hungarian
persons.
Fig. 1 Photographs, head circumference chart and brain MR images. a,
b The patient at the age of 2 (a) and 6 (b) years. Note prominent
forehead, arched eyebrows, strabismus, ﬂat, wide nasal bridge, short
nose with a broad tip, long philtrum, small lower jaw and low-set ears
with abnormally modelled helices. c The chart shows the progressive
growth of the head circumference. d Bilateral skin tags on the ﬁfth
ﬁngers. e Sagittal T1-weighted MR image at the age of 3 months
shows the partial agenesis of the corpus callosum with a thin remnant
of the anterior part of the body (arrow). f Axial T2-weighted MR
image at the age of 4 years demonstrates the thin anterior part of the
corpus callosum, dilated ventricles and widely separated leaves
(arrows) of the septum pellucidum
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Results
Chromosomal analysis showed a normal 46,XX karyotype.
Copy number changes were not found by Affymetrix 750K
array. Clinical exome (Trusight One panel) sequencing
revealed heterozygous variants in exon 18 of the FOXP1
(NM_032682.5:c.1573C>T, NP_116071.2:p.Arg525Ter)
and exon 17 of the PTCH1 (NM_000264.4:c.2834delGin-
sAGATGTTGTGGACCC, NP_000255.2:p.Arg945Glnf-
sTer22) genes in the patient (Figs. 2 and 3). The FOXP1
variant has been reported earlier as a nonsense pathogen
mutation (rs112795301, RCV000005214), while the
PTCH1 variant (RCV000655932) has not been found in
either dbSNP, ClinVar, ExAC or EVS databases or a cohort
of 140 unrelated Hungarian controls. Sanger sequencing
conﬁrmed both variants as de novo mutations in the patient.
They were not present either in the parents or in the
patient’s healthy brother (Figs. 2 and 3).
Discussion
We describe heterozygous disruptions in two genes, namely
FOXP1 and PTCH1. Megalencephaly has been described in
both FOXP1- and PTCH1-related conditions; however,
such an extreme rate of head growth, as seen in our patient,
has never been reported in association with disease-causing
variants in either FOXP1 [3–5] or PTCH1 [8, 10–13] genes.
Although structural brain abnormalities have been found
occasionally in FOXP1-related disorders, dysmorphic cor-
pus callosum has been reported only in a single case [3, 4].
Brain malformations were also rarely reported in PTCH1
mutation [10–12], notwithstanding corpus callosum
agenesis, dysgenesis and hypoplasia occurred in a few
patients [11, 13, 14]. It seems that the intellectual disability
and language deﬁcit were less severe in children with
mutations only in one of these genes [3–5, 8, 10–13]. We
suggest that the effects of multiple hits, disruptive disease-
causing variants in two different genes simultaneously
added and resulted in the serious composite clinical phe-
notype in our patient (Table 1).
Functional characterization of FOXP1 variants [4, 15]
provided evidence that the de novo heterozygous nonsense
mutation, c.1573C>T, p.Arg525Ter, found in our patient,
was pathogenic [4, 15]. FOXP proteins regulate gene
expression by forming homo- and hetero-dimers with each
other and they interact with other transcription factors
forming a network involved in cortical development [16].
Studies on embryonic neural stem cells and mice with
Foxp1 down-regulation or deletion in the developing fore-
brain conﬁrmed that an extensive signalling network regu-
lated by Foxp1 is involved in important developmental
processes such as neurogenesis, neuronal migration and
differentiation [17–19].
Several hundred pathogenic variants in the PTCH1 gene
have been described [6, 7]. The novel de novo heterozygous
variant c.2834delGinsAGATGTTGTGGACCC, p.
Arg945GlnfsTer22, in our patient causes truncation of one
of the extracellular loops of the PTCH1 leading to the loss
of a signiﬁcant part of the C-terminal protein, including ﬁve
transmembrane domains [6]. The PTCH1 protein is a
member of the HH receptor complex in the primary cilia. It
represses Smoothened (SMO), which is a member of the G-
protein-coupled receptor superfamily. The truncated
PTCH1 protein probably fails to inhibit SMO activation
resulting in dysregulation of the HH signalling pathway. We
Fig. 2 FOXP1 mutation.
Mutation in FOXP1 gene
(NM_032682.5) at c.1573
position results in a STOP
codon. The mutation is very
likely de novo since it was
absent in the parents (a). The
mutated position is highlighted
in the DNA sequence of the
affected child. Standard IUPAC
(International Union of Pure and
Applied Chemistry) nucleotide
ambiguity DNA code (Y= T/C)
used (b)
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Table 1 Common versus distinct
clinical features attributable to
mutations in FOXP1 and
PTCH1
FOXP1 (refs. [2–5]) PTCH1 (refs. [7, 8, 10–14])
Head size Extreme megalencephaly (macrocephaly)











Symmetrical post-axial cutaneous appendages (skin
tags) on both hands
Brain imaging Partial agenesis of the corpus callosum
Widely separated leaves of the septum pellucidum
Enlarged ventricles
Neurological signs Global developmental delay
Profound intellectual disability
Generalized hypotonia
Fig. 3 PTCH1 mutation. a The complex PTCH1 variant caused by a
single-nucleotide deletion and a 15 bp long insertion in exon 17 which
causes a premature STOP codon (NP_000255.2:p.Arg945GlnfsTer22).
The mutated portion of the sequence is highlighted in red. The
mutation is very likely de novo since it was absent in the parents. b
The presence of PTCH1 (NM_000264.4) mutation at DNA level
conﬁrmed by Sanger sequencing in the affected child. It was absent in
the parents. The complex mutation starts after the highlighted portion
of the sequence (blue). c The sequence alignment of the reference and
mutated PTCH1 alleles
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can hypothesize that the extreme large volume of the brain
tissue in our patient can partly be related to persistent HH
pathway activation [20].
Further studies on possible functional interactions
between FOXP1 and PTCH1 may clarify the molecular
basis of this phenotype.
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